tetano
Editor, Senior Moderator
Inform Med Unlocked
. 2023;39:101256.
doi: 10.1016/j.imu.2023.101256. Epub 2023 Apr 25. Mutations of SARS-CoV-2 and their impact on disease diagnosis and severity
Laiali Alquraan[SUP] 1 [/SUP], Karem H Alzoubi[SUP] 2 3 [/SUP], Suzie Y Rababa'h[SUP] 4 [/SUP]
Affiliations
Numerous variations of the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), including D614G, B.1.1.7 (United Kingdom), B.1.1.28 (Brazil P1, P2), CAL.20C (Southern California), B.1.351 (South Africa), B.1.617 (B.1.617.1 Kappa & Delta B.1.617.2) and B.1.1.529, have been reported worldwide. The receptor-binding domain (RBD) of the spike (S) protein is involved in virus-cell binding, where virus-neutralizing antibodies (NAbs) react. Novel variants in the S-protein could maximize viral affinity for the human angiotensin-converting enzyme 2 (ACE2) receptor and increase virus transmission. Molecular detection with false-negative results may refer to mutations in the part of the virus's genome used for virus diagnosis. Furthermore, these changes in S-protein structure alter the neutralizing ability of NAbs, resulting in a reduction in vaccine efficiency. Further information is needed to evaluate how new mutations may affect vaccine efficacy.
Keywords: COVID-19; Disease diagnosis; Mutations; SARS-CoV-2; Variants.
. 2023;39:101256.
doi: 10.1016/j.imu.2023.101256. Epub 2023 Apr 25. Mutations of SARS-CoV-2 and their impact on disease diagnosis and severity
Laiali Alquraan[SUP] 1 [/SUP], Karem H Alzoubi[SUP] 2 3 [/SUP], Suzie Y Rababa'h[SUP] 4 [/SUP]
Affiliations
- PMID: 37131549
- PMCID: PMC10127666
- DOI: 10.1016/j.imu.2023.101256
Numerous variations of the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), including D614G, B.1.1.7 (United Kingdom), B.1.1.28 (Brazil P1, P2), CAL.20C (Southern California), B.1.351 (South Africa), B.1.617 (B.1.617.1 Kappa & Delta B.1.617.2) and B.1.1.529, have been reported worldwide. The receptor-binding domain (RBD) of the spike (S) protein is involved in virus-cell binding, where virus-neutralizing antibodies (NAbs) react. Novel variants in the S-protein could maximize viral affinity for the human angiotensin-converting enzyme 2 (ACE2) receptor and increase virus transmission. Molecular detection with false-negative results may refer to mutations in the part of the virus's genome used for virus diagnosis. Furthermore, these changes in S-protein structure alter the neutralizing ability of NAbs, resulting in a reduction in vaccine efficiency. Further information is needed to evaluate how new mutations may affect vaccine efficacy.
Keywords: COVID-19; Disease diagnosis; Mutations; SARS-CoV-2; Variants.